Presenting at the London Value Conference, Michael Price pitches Hospira (HSP) - a stock the...

|By:, SA News Editor

Presenting at the London Value Conference, Michael Price pitches Hospira (HSP) - a stock the growth investors have unloaded to the value guys after the FDA shut down one of its largest plants. He expects the company to have completely recovered within 2 years. He's also bullish on HESS, trading at a 50% discount to intrinsic value amid its proxy fight with Elliot - the outcome of which will see 4-5 new directors, and a split or even buyout of the company. A bearish idea: Berkshire Hathaway (BRK.A, BRK.B) is 20% overvalued.